| Literature DB >> 32174212 |
Xiaolei Yang1, Tesfaldet Habtemariam Hidru1, Xu Han1, Xinyuan Zhang2, Yang Liu1, Binhao Wang3, Huihua Li1, Shouling Wu4, Yun-Long Xia1.
Abstract
Background Elevated long-term systolic blood pressure and resting heart rate (RHR) variability are suggested to amplify the risk of all-cause mortality (ACM). However, the link between increased RHR and pulse pressure for ACM remained unclear. Methods and Results This study analyzed 46 751 individuals from Kailuan Cohort Study for the end outcome of ACM. A Cox regression model was used to estimate hazard ratios for death events. Kaplan-Meier analysis was performed to study the differences in survival as stratified by the SD, coefficient of variation, and average real variability of RHR and pulse pressure quartiles. A total of 1667 deaths (<65 years of age=866/40351, ≥65 years of age=801/6400) were recorded over 4.97±0.69 years follow-up. Participants under the age of 65 years in the third and fourth quartiles of pulse pressure SD had an independent increase in risk for ACM (hazard ratio [95% CI], 1.16 [1.06-1.28]; and 1.19 [1.05-1.35], respectively). Additionally, participants >65 years of age had a higher risk for ACM across quartiles of RHR-SD. The hazard ratio (95% CI) for the subjects in quartiles 2, 3, and 4 were 1.81 (1.10-2.97), 2.31 (1.37-1.3.90), and 2.64 (1.63-4.29), respectively. Conclusions An elevated long-term RHR variability combined with an increased pulse pressure variability or vice versa amplifies the risk of ACM.Entities:
Keywords: all‐cause death; blood pressure; heart rate; pulse pressure
Mesh:
Year: 2020 PMID: 32174212 PMCID: PMC7335531 DOI: 10.1161/JAHA.119.014122
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1Flowchart of the follow‐up period and participants included in the Kailuan Cohort Study.
Age‐Specific Baseline Clinical Characteristics of Participants by Quartiles of SD in PP Variability
| Quartile of SD in PP, mm Hg | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| <65 Y |
| ≥65 Y |
| |||||||
| Quartile 1 <4.7 | Quartile 2 4.7–6.4 | Quartile 3 6.4– 10.0 | Quartile 4 ≥10.0 | Quartile 1 <5.8 | Quartile 2 5.8–9.6 | Quartile 3 9.6–13.7 | Quartile 4 ≥13.7 | |||
| Participants, n | 10 087 | 10 088 | 10 070 | 10 106 | … | 1597 | 1603 | 1600 | 1600 | … |
| Age (±SD), years | 48.0±9.3 | 48.6±9.4 | 49.6±9.0 | 51.9±8.5 | <0.001 | 71.5±4.7 | 71.6±4.9 | 71.8±4.9 | 72.7±5.3 | <0.001 |
| Men, % | 76.8 | 76.7 | 78.0 | 77.2 | 0.102 | 84.2 | 84.5 | 83.3 | 82.3 | 0.335 |
| BMI (±SD), kg/m2 | 25.0±3.3 | 25.0±3.3 | 25.1±3.4 | 25.4±3.4 | <0.001 | 24.9±3.5 | 25.0±3.4 | 25.2±3.4 | 25.3±3.5 | 0.006 |
| Current smoker, % | 38.3 | 37.9 | 37.5 | 35.6 | <0.001 | 19.9 | 18.3 | 16.4 | 15.5 | 0.005 |
| High/intensive activity, % | 11.2 | 11.3 | 12.4 | 12.7 | 0.001 | 20.8 | 20.1 | 20.6 | 16.4 | 0.004 |
| Mean SBP (±SD), mm Hg | 123.7±13.9 | 124.6±14.4 | 127.5±15.0 | 135.3±17.3 | <0.001 | 136.2±16.7 | 138.7±16.2 | 141.5±16.3 | 148.5±16.4 | <0.001 |
| Mean DBP (±SD), mm Hg | 81.9±8.7 | 82.3±8.7 | 83.7±9.0 | 86.6±9.8 | <0.001 | 83.1±8.3 | 84.1±8.5 | 84.3±8.5 | 85.6±8.5 | <0.001 |
| Mean heart rate (±SD), beats/min | 73.6±7.6 | 73.5±7.6 | 73.8±7.7 | 74.5±8.2 | <0.001 | 72.8±8.5 | 72.8±8.3 | 73.1±8.2 | 73.0±8.6 | 0.671 |
| TC (±SD), mmol/L | 4.9±1.0 | 5.0±1.4 | 5.0±1.3 | 5.0±1.2 | <0.001 | 5.1±1.0 | 5.1±1.4 | 5.0±1.0 | 5.2±2.0 | 0.020 |
| HDL (±SD), mmol/L | 1.5±0.5 | 1.5±0.5 | 1.5±0.5 | 1.5±0.5 | 0.337 | 1.6±0.6 | 1.5±0.4 | 1.5±0.5 | 1.5±0.4 | 0.116 |
| FPG (±SD), mmol/L | 5.5±1.6 | 5.6±1.6 | 5.6±1.6 | 5.8±2.0 | <0.001 | 5.8±1.6 | 5.8±1.6 | 6.0±1.8 | 6.0±1.7 | 0.002 |
| CRP>2 mg/L, % | 29.1 | 28.8 | 29.5 | 32.4 | <0.001 | 40.4 | 40.6 | 42.8 | 45.4 | 0.014 |
| Diabetes mellitus, % | 7.6 | 7.9 | 8.6 | 12.4 | <0.001 | 12.3 | 12.4 | 14.4 | 15.6 | 0.013 |
| Hypertension, % | 31.7 | 35.5 | 41.3 | 58.9 | <0.001 | 53.1 | 60.9 | 69.6 | 79.4 | <0.001 |
| Antihypertensive medication drug class, % | ||||||||||
| ACE inhibitor | 0.7 | 0.5 | 0.9 | 1.2 | <0.001 | 1.0 | 1.0 | 1.7 | 2.1 | 0.017 |
| ARB | 0.1 | 0.2 | 0.2 | 0.4 | 0.001 | 0.3 | 0.4 | 0.7 | 1.1 | 0.025 |
| Calcium channel blocker | 0.7 | 0.6 | 0.7 | 1.2 | <0.001 | 2.3 | 2.8 | 3.3 | 2.9 | 0.340 |
| Diuretic | 0.6 | 0.5 | 0.8 | 1.3 | <0.001 | 0.8 | 0.6 | 1.4 | 1.8 | 0.010 |
| α‐Blocker | 0.0 | 0.0 | 0.0 | 0.1 | 0.576 | 0.0 | 0.1 | 0.0 | 0.2 | 0.112 |
| Combination tablets | 0.7 | 0.7 | 1.1 | 1.7 | <0.001 | 1.7 | 2.0 | 3.5 | 3.4 | 0.001 |
ACE indicates angiotensin converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CRP, C‐reactive protein; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high‐density lipoprotein; HR, heart rate; PP, pulse pressure; SBP, systolic blood pressure; and TC, total cholesterol.
Age‐Specific Baseline Clinical Characteristics of Participants by Quartiles of SD in RHR Variability
| Quartile of SD in RHR, beats/min |
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| <65 Y |
| ≥65 Y | ||||||||
| Quartile 1 <3.5 | Quartile 2 3.5–5.8 | Quartile 3 5.8–8.5 | Quartile 4 ≥8.5 | Quartile 1 <4.0 | Quartile 2 4.0–6.1 | Quartile 3 6.1–9.0 | Quartile 4 ≥9.0 | |||
| Participants, n | 10 169 | 9912 | 10 260 | 10 010 | ‐ | 1597 | 1591 | 1589 | 1623 | … |
| Age (±SD), years | 49.6±9.2 | 50.0±9.1 | 49.4±9.3 | 49.5±9.3 | 0.794 | 71.8±4.9 | 71.7±4.8 | 72.0±5.0 | 72.1±5.1 | 0.092 |
| Men, % | 74.8 | 76.0 | 77.7 | 80.3 | <0.001 | 81.3 | 83.0 | 84.2 | 85.6 | 0.009 |
| BMI (±SD), kg/m2 | 25.2±3.3 | 25.1±3.3 | 25.1±3.3 | 25.1±3.4 | 0.472 | 25.1±3.5 | 25.2±3.3 | 25.1±3.4 | 25.1±3.5 | 0.796 |
| Current smoker, % | 36.3 | 36.8 | 38.1 | 38.1 | 0.015 | 17.2 | 17.1 | 18.3 | 17.6 | 0.792 |
| High/intensive activity, % | 12.1 | 11.6 | 11.8 | 12.0 | 0.679 | 19.5 | 19.6 | 19.6 | 19.1 | 0.986 |
| Mean SBP (±SD), mm Hg | 126.4±15.6 | 126.9±15.3 | 127.6±15.6 | 130.2±16.8 | <0.001 | 140.0±16.5 | 140.6±17.1 | 141.5±17.1 | 142.7±17.4 | <0.001 |
| Mean DBP (±SD), mm Hg | 82.9±9.0 | 83.2±9.1 | 83.4±9.1 | 84.9±9.6 | <0.001 | 83.7±8.3 | 83.9±8.3 | 84.3±8.5 | 85.1±8.9 | <0.001 |
| Mean heart rate (±SD), beats/min | 71.8±6.8 | 72.5±6.9 | 73.7±7.5 | 77.3±8.7 | <0.001 | 70.6±7.3 | 71.9±7.6 | 72.8±7.8 | 76.3±9.5 | <0.001 |
| TC (±SD), mmol/L | 5.0±1.4 | 5.0±1.2 | 5.0±1.0 | 5.0±1.3 | 0.051 | 5.1±1.5 | 5.1±1.0 | 5.1±2.0 | 5.1±1.1 | 0.910 |
| HDL (±SD), mmol/L | 1.5±0.5 | 1.5±0.5 | 1.5±0.5 | 1.5±0.5 | 0.320 | 1.6±0.5 | 1.5±0.4 | 1.5±0.6 | 1.6±0.5 | 0.382 |
| FPG (±SD), mmol/L | 5.6±1.9 | 5.6±1.7 | 5.6±1.5 | 5.7±1.7 | <0.001 | 5.8±1.6 | 5.8±1.5 | 5.9±1.7 | 6.1±1.9 | <0.001 |
| CRP>2 mg/L, % | 28.6 | 28.9 | 30.4 | 31.8 | <0.001 | 39.9 | 43.7 | 40.9 | 44.5 | 0.020 |
| Diabetes mellitus, % | 8.3 | 8.9 | 8.7 | 10.6 | <0.001 | 12.6 | 11.7 | 12.5 | 17.9 | <0.001 |
| Hypertension, % | 39.9 | 41.2 | 40.9 | 45.5 | <0.001 | 65.2 | 64.9 | 66.6 | 66.2 | 0.696 |
| Antihypertensive medication drug class, % | ||||||||||
| ACE inhibitor | 0.7 | 0.6 | 0.8 | 1.1 | 0.004 | 1.3 | 0.9 | 1.8 | 1.8 | 0.146 |
| ARB | 0.2 | 0.3 | 0.2 | 0.2 | 0.410 | 0.8 | 0.4 | 0.7 | 0.6 | 0.548 |
| Calcium channel blocker | 0.8 | 0.9 | 0.7 | 0.9 | 0.320 | 2.8 | 2.1 | 3.2 | 3.3 | 0.156 |
| Diuretic | 0.8 | 0.8 | 0.8 | 0.9 | 0.873 | 0.9 | 1.2 | 1.1 | 1.4 | 0.719 |
| α‐Blocker | 0.0 | 0.1 | 0.0 | 0.1 | 0.009 | 0.1 | 0.1 | 0.1 | 0.1 | 1.000 |
| Combination tablets | 1.0 | 0.9 | 0.9 | 1.3 | 0.028 | 2.8 | 2.1 | 2.7 | 2.8 | 0.571 |
ACE indicates angiotensin converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CRP, C‐reactive protein; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL, high‐density lipoprotein; RHR, resting heart rate; SBP, systolic blood pressure; and TC, total cholesterol.
Cumulative Mortality and HRs (95% CIs) for All‐Cause Mortality Associated With Quartile of SD of RHR Variability and PP Variability in Participants <65 Years of Age
| Quartile of RHR‐SD Variability, beats/min |
| ||||
|---|---|---|---|---|---|
| Quartile 1 (<3.5) | Quartile 2 (3.5–5.8) | Quartile 3 (5.8–8.5) | Quartile 4 (≥8.5) | ||
| Total, n | 10 169 | 9912 | 10 260 | 10 010 | ‐ |
| Deaths, n (%) | 148 (1.5) | 183 (1.8) | 256 (2.5) | 279 (2.8) | <0.001 |
| Model 1 | 1.00 (Ref) | 1.28 (1.03, 1.58) | 1.72 (1.41, 2.11) | 1.93 (1.58, 2.35) | <0.001 |
| Model 2 | 1.00 (Ref) | 1.28 (1.03, 1.59) | 1.71 (1.39, 2.09) | 1.86 (1.52, 2.27) | <0.001 |
| Model 3 | 1.00 (Ref) | 1.28 (1.03, 1.60) | 1.48 (1.20, 1.83) | 1.59 (1.29, 1.96) | <0.001 |
ACE indicates angiotensin‐converting enzyme; ARV, average real variability; CV, coefficient of variation; HR, hazard ratio; PP, pulse pressure; and RHR, resting heart rate.
Unadjusted model.
Adjusted for age and sex.
Adjusted for age and sex, body mass index, current smoker, mean PP, mean RHR, fasting plasma glucose, total cholesterol, high‐density lipoprotein, elevated C‐reactive protein, and ACE inhibitor.
Cumulative Mortality and HRs (95% CI) for All‐Cause Mortality Associated With Quartile of SD of RHR Variability and PP Variability in Participants >65 Years of Age
| Quartile of RHR‐SD Variability, beats/min |
| ||||
|---|---|---|---|---|---|
| Quartile 1 (<4.0) | Quartile 2 (4.0–6.1) | Quartile 3 (6.1–9.0) | Quartile 4 (≥9.0) | ||
| Total, n | 1597 | 1591 | 1589 | 1623 | … |
| Deaths, n (%) | 147 (9.2) | 205 (12.9) | 212 (13.3) | 237 (14.6) | <0.001 |
| Model 1 | 1.00 (Ref) | 1.42 (1.15, 1.76) | 1.48 (1.20, 1.83) | 1.64 (1.33, 2.01) | <0.001 |
| Model 2 | 1.00 (Ref) | 1.44 (1.17, 1.78) | 1.44 (1.16, 1.77) | 1.57 (1.28, 1.93) | <0.001 |
| Model 3 | 1.00 (Ref) | 1.33 (1.07, 1.65) | 1.35 (1.09, 1.68) | 1.41 (1.13, 1.75) | 0.035 |
ACE indicates angiotensin‐converting enzyme; ARV, average real variability; CV, coefficient of variation; HR, hazard ratio; PP, pulse pressure; and RHR, resting heart rate.
Unadjusted model.
Adjusted for age and sex.
Adjusted for age and sex, body mass index, current smoker, mean PP, mean RHR, fasting plasma glucose, total cholesterol, high‐density lipoprotein, elevated C‐reactive protein, and ACE inhibitor.
Figure 2Adjusted hazard ratios with 95% CIs for 1 SD/CV/ARV increase in SD/CV/ARV resting heart rate variability and pulse pressure variability of all‐cause mortality.ARV indicates average real variability; CV, coefficient of variation; and SD, standard deviation.
Figure 3Absolute risk of mortality by quartiles of the SD of long‐term variability in pulse pressure and resting heart rate variability for participants younger and older than 65 years of age.
Figure 4The Kaplan–Meier survival curves for all‐cause mortality.
The Kaplan–Meier survival curves of participants ˂65 by quartiles of RHR‐SD (
Figure 5The smoothing curve of Schoenfeld partial residuals against time rank.The smoothing curve of RHR‐SD (
Figure 6The actual changes in hemodynamic parameters from the first visit to the last visit among participants <65 years of age.
Figure 7The actual changes in hemodynamic parameters from the first visit to the last visit among participants >65 years of age.
Figure 8Sensitivity analyses.